Testing

CPT code updates posted to mayocliniclabs.com during the month of December.

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.

The following list includes updates posted to mayocliniclabs.com during the month of November.

Michelle Kluge, M.S., CGC, explains how Mayo Clinic Laboratories’ CYPZ assay provides accurate testing for congenital adrenal hyperplasia. Using an in-depth methodology that incorporates Sanger sequencing, MCL can provide clear answers for carriers and individuals clinically affected by the most common form of CAH.

Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.

Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' PCR assay that identifies two recently described staphylococcus species. The assay is unique in its ability to distinguish the new organisms from Staphylococcus aureus, providing clearer results that ultimately improve patient care.

In November 2021, Mayo Clinic Laboratories announced thirty four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The following list includes updates posted to mayocliniclabs.com during the month of October.

In October 2021, Mayo Clinic Laboratories announced eleven new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.

The following list includes updates posted to mayocliniclabs.com during the month of September.

Linda Hasadsri, M.D., Ph.D., explains how Mayo Clinic Laboratories’ inclusive approach to mitochondrial disease testing expedites diagnosis. Using innovative methodologies like custom reagents and droplet digital PCR enables precision insights on prognosis and treatment options.

Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.